[12] Patent
[11] Patent No.:GC0007561  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/125993
Date of the Decision to Grant the Patent:14/Apr/2018

[21] Application No.:GC 2010-17386

[22] Filing Date:18/12/2010

[30] Priority:

[33] State [32] Priority date [31] Priority No.
DK
17/12/2009
200901339

[72] Inventors:1- Ask Püschl،2- Jacob Nielsen،3- Jan Kehler،4- John Paul Kilburn،5- Mauro Marigo،6- Morten Langgard

[73] Owner: H. LUNDBECK A/S, 9 Ottiliavej, Valby, DK -2500, Denmark

[74] Agent: Suleiman I. Al-Ammar Law Office

  

 

  

[51]IPC:
Int. Cl.: A61K 31/519; A61P 25/00; C07D 471/04, 487/04 (2006.01)

[56] Cited Documents:

-WO 2009152825 A1 (LUNDBECK & CO AS H[oK]; RITZEN ANDREAS [DK]; KEHLER JAN[DK]; LANGGAA) 23 December 2009
-US 2010016303 A1 (RITZEN ANDREAS [BK] ETAL) 21 January 2010
 
Examiner: PH. Sultana K. AlOudah

[54] HETEROAROMATIC PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS
[57] Abstract: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.
No. of claims: 29


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.